Skip to main content
Skip to navigation
PR News
Expand Search
Menu
Access
myPennMedicine
Home
News Releases
RSS Feed
News Releases
Browse By:
Month:
All
January
February
March
April
May
June
July
August
September
October
November
December
Year:
All
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
Apply Filter
Showing 1-10 of 43
10
50
100
results per page
1
2
3
Energizing the Immune System to Eat Cancer
January 21, 2019
Immune cells called macrophages are supposed to serve and protect, but cancer has found ways to put them to sleep. Now researchers at the Abramson Cancer Center of the University of Pennsylvania say they’ve identified how to fuel macrophages with the energy needed to attack and eat cancer cells.
Cancer
Penn’s Abramson Cancer Center Welcomes New Director’s Leadership Council Chair
January 15, 2019
The Abramson Cancer Center at the University of Pennsylvania announced today that Richard S. Schiffrin, Esq., has been appointed chair of the Center Director’s Leadership Council (ACCDLC), replacing outgoing chair Richard W. Vague.
Cancer
Two Ways Cancer Resists Treatment Are Actually Connected, with One Activating the Other
December 18, 2018
Drugs that target BRAF and MEK in cancer have shown promise in treating a subset of melanoma that carries a mutation in the BRAF gene, but drug resistance usually emerges, reversing the benefit of these drugs and limiting the survival of patients.
Cancer
New Imaging Tools that Trace Key Breast Cancer Enzymes May Help Guide Therapies
December 06, 2018
A set of emerging diagnostic tools may help identify breast cancer patients who are most likely to benefit from therapies that target important enzymes fueling a range of subtypes, including BRCA-mutated and triple negative cancers.
Cancer
Global Trial Shows CAR T Therapy Can Lead to Durable Remissions in Non-Hodgkin’s Lymphoma
November 30, 2018
In an update to a global clinical trial stretching from Philadelphia to four continents, the chimeric antigen receptor (CAR) T cell therapy Kymriah® (tisagenlecleucel, formerly CTL019) led to long-lasting remissions in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
Cancer
FDA Approves New Targeted Drug for Leukemia Tested at University of Pennsylvania
November 28, 2018
The U.S. Food and Drug Administration (FDA) has approved the first ever inhibitor drug specifically approved for treating patients with relapsed or refractory acute myeloid leukemia (AML) with a mutation in the Fms-like tyrosine kinase 3 (FLT3) gene.
Cancer
CAR T Studies Highlight Abramson Cancer Center Research at ASH Annual Meeting
November 26, 2018
From better-understanding how to improve response rates in multiple myeloma patients to identifying why some patients with other types of cancer are resistant in the first place, research from the Abramson Cancer Center of the University of Pennsylvania continues to pace the field in expanding knowledge of cellular therapies for cancer care.
Cancer
Abramson Cancer Center Joins National Comprehensive Cancer Network
November 20, 2018
The Abramson Cancer Center (ACC) at the University of Pennsylvania announced today that it is joining the National Comprehensive Cancer Network® (NCCN®) as its 28th member institution. The ACC joins top academic cancer centers from across the United States in creating the most frequently updated cancer care guidelines worldwide.
Cancer
Anti-Malaria Drugs Have Shown Promise in Treating Cancer, and Now Researchers Know Why
November 15, 2018
Anti-malaria drugs known as chloroquines have been repurposed to treat cancer for decades, but until now no one knew exactly what the chloroquines were targeting when they attack a tumor. Now, researchers from the Abramson Cancer Center of the University of Pennsylvania say they have identified that target – an enzyme called PPT1 – opening up a new pathway for potential cancer treatments.
Cancer
Abramson Cancer Center Receives $10.7 Million to Study CAR T Cells in Solid Tumors
October 22, 2018
A new program project grant from the National Cancer Institute (NCI) will fund research by the Translational Center of Excellence for Lung Cancer Immunology at the Abramson Cancer Center of the University of Pennsylvania to improve the effectiveness of chimeric antigen receptor (CAR) T cell therapy at fighting solid tumors.
Cancer
Showing 1-10 of 43
10
50
100
results per page
1
2
3
Contacts
For Patients and the General Public:
1-800-789-7366
Share This Page:
Post
Tweet
Share
News Releases
News Blog
Publications & Special Projects
Internal Newsletters
Subscribe
Media Resources and Contacts